Bluejay Diagnostics (NASDAQ:BJDX) Shares Set to Reverse Split on Thursday, June 20th

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) shares are going to reverse split on Thursday, June 20th. The 1-8 reverse split was announced on Thursday, June 20th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, June 20th.

Bluejay Diagnostics Trading Down 20.4 %

Shares of BJDX stock opened at $0.41 on Tuesday. Bluejay Diagnostics has a 1-year low of $0.34 and a 1-year high of $13.98. The company has a market capitalization of $1.09 million, a price-to-earnings ratio of -0.05 and a beta of 1.06. The stock’s fifty day simple moving average is $0.54 and its 200-day simple moving average is $1.04.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($1.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($1.10).

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 24,230 shares of the company’s stock, valued at approximately $30,000. Armistice Capital LLC owned approximately 1.95% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is currently owned by institutional investors and hedge funds.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.